Gene therapy for gliomas: Molecular targets, adenoviral vectors, and oncolytic adenoviruses

Experimental Cell Research

Volumn 252, Issue 1, 1999, Pages 1-12

  Alemany, Ramon ^b   Gomez Manzano, Candelaria ^a   Balagué, Cristina ^b   Alfred Yung, W K ^a   Curiel, David T ^b   Kyritsis, Athanassios P ^a   Fueyo, Juan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Adenovirus; Gene therapy; Glioma; Tumor suppressor genes

Indexed keywords

GROWTH FACTOR; PROTEIN P16; PROTEIN P53; VIRUS VECTOR;

ADENOVIRUS; DRUG EFFECT; GENE INACTIVATION; GENE MUTATION; GENE OVEREXPRESSION; GENE TARGETING; GENE THERAPY; GLIOMA; PRIORITY JOURNAL; REVIEW; TUMOR CELL; TUMOR SUPPRESSOR GENE; VIRUS REPLICATION;

EID: 0033544004     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1006/excr.1999.4623     Document Type: Review

References (71)

1. Levin V. A., Leivel S., Gutin P. H. Neoplasms of the central nervous system. DeVita V. T., Hellman S. J., Rosemberg S. A. Cancer: Principles and Practice Of Oncology. 1997;Lippincott, Philadelphia.
2. Roth J. A., Cristiano R. J. Gene therapy for cancer: What have we done and where are we going. J. Natl. Cancer Inst. 89:1997;21-39.
3. Collins V. P., James C. D. Gene and chromosomal alterations associated with the development of human gliomas. FASEB J. 7:1993;926-930.
4. Furnari F. B., Huang H. J., Cavenee W. K. Genetics and malignant progression of human brain tumours. Cancer Surv. 25:1995;233-275.
5. Kleihues P., Ohgaki H. Genetics of glioma progression and the definition of primary and secondary glioblastoma. Brain Pathol. 7:1997;1131-1136.
6. Fueyo J., Gomez-Manzano C., Yung W. K. A., Kyritsis A. P. The funcional role of tumor suppressor genes in gliomas: Clues for future therapeutic strategies. Neurology. 51:1998;1250-1255.
7. Gomez-Manzano C., Fueyo J., Kyritsis A. P., Yung W. K. Tumor suppressor gene therapy for brain tumors. Chiocca A. E., Breakefield X. Gene Transfer and Therapy for Neurological Disorders. 1998;Human Press, Totowa.
8. Nigro J. M., Baker S. J., Preisinger A. C. Mutations in the p53 gene occur in diverse human tumour types. Nature. 342:1989;705-708.
9. Sidransky D., Mikkelsen T., Schwechheimer K., Rosenblum M. L., Cavanee W., Vogelstein B. Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature. 355:1992;846-847.
10. Gomez-Manzano C., Fueyo J., Kyritsis A. P., Steck P. A., Roth J. A., McDonnell T. J., Steck K. D., Levin V. A., Yung W. K. A. Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Cancer Res. 56:1996;694-699.
11. Gomez-Manzano C., Fueyo J., Kyritsis A. P., McDonnell T. J., Steck P. A., Levin V. A., Yung W. K. A. Characterization of p53 and p21 functional interactions in glioma cells en route to apoptosis. J. Natl. Cancer Inst. 14:1997;1036-1044.
12. Sandig V., Brand K., Herwing S., Lukas J., Bartek J., Strauss M. Adenovirally transferred p16INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death. Nat. Med. 3:1997;313-319.
13. Evan G., Littlewood T. A matter of life and cell death. Science. 281:1998;1317-1322.
14. Ueki K., Ono Y., Henson J. W., Efird J. T., von Deimling A., Louis D. N. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res. 56:1996;150-153.
15. Fueyo J., Gomez-Manzano C., Bruner J. M., Saito Y., Zhang B., Levin V. A., Yung W. K. A., Kyritsis A. P. Hypermethylation of the CpG island of p16/CDKN2 correlates with gene inactivation in gliomas. Oncogene. 13:1996;1615-1619.
16. Fueyo J., Gomez-Manzano C., Yung W. K. A., Clayman G. L., Liu T.-J., Bruner J. M., Levin V. A., Kyritsis A. P. Adenovirus-mediated p16/CDKN2 gene transfer induces growth arrest and modifies the transformed phenotype of glioma cells. Oncogene. 12:1996;103-110.
17. Fueyo J., Gomez-Manzano C., Yung W. K. A., Liu T. J., Alemany R., Bruner J. M., Chintala S. K., Rao J. S., Levin V. A., Kyritsis A. P. Suppression of human glioma growth by adenovirus-mediated Rb gene transfer. Neurology. 50:1998;1307-1315.
18. Fueyo J., Gomez-Manzano C., Yung W. K. A., Liu T. J., Alemany R., McDonnell T. J., Xhi X., Rao J. S., Levin V. A., Kyritsis A. P. Overexpression of E2F-1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo. Nat. Med. 4:1998;685-690.
19. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S. I., Puc J., Miliaresis C., Rodgers L., McCombie R., Bigner S. H., Llovanella B. C., Ittmann M., Tycko B., Hibshoosh H., Wigler M. H., Parsons R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast and prostate cancer. Science. 275:1997;1943-1946.
20. Steck P. A., Pershouse M. A., Jasser S. A., Yung W. K., Lin H., Ligon A. H., Lanford L., Baumgard M. L., Hattier T., Davis T., Frye C., Hu R., Swedlund B., Teng D. H., Tavtigian S. V. Identification of a candidate tumor suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. 15:1997;356-362.
21. Cheney W., Johnson D. E., Vaillancort M.-T., Avanzini J., Morimoto A., Demers G. W., Wills K. N., Shabarm P. W., Bolen J. B., Tavtigian S. V., Bookstein R. Suppression of tumorigenicity of glioblastoma cells by adenovirus-mediated MMAC1/PTEN gene transfer. Cancer Res. 58:1998;2331-2334.
22. Hsu S. C., Volpert O. V., Steck P. A., Mikkelsen T., Polverini P. J., Rao S., Chou P., Bouck N. P. Inhibition of angiogensis in human glioblastomas by chromosome 10 induction of thrombospondin-1. Cancer Res. 15:1996;5684-5691.
23. Im S.-A., Gomez-Manzano C., Fueyo J., Liu T. J., Ke L. D., Kim J. S., Lee H. Y., Steck P. A., Kyritsis A. P., Yung W. K. Antiangionesis treatment for gliomas: Transfer of antisense-VEGF inhibits tumor growth in vivo. Cancer Res. 59:1999;895-900.
24. Collis V. P. Gene amplification in human gliomas. Glia. 15:1995;289-296.
25. Cambell J. W., Pollack F. Growth factors in gliomas: Antisense and dominant negative mutant strategies. J. Neuro-Oncol. 35:1997;275-285.
26. Nagane N., Coufal F., Lin H., Bogler O., Cavenee W. K., Huang H.J. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res. 56:1996;5079-5086.
27. Uhm J. H., Dooley N. P., Villemure J. G., Yong V. W. Mechanisms of glioma invasion: Role of matrix-metalloproteinases. Can. J. Neurol. Sci. 24:1997;3-15.
28. Kleihues P., Burger P. C., Plate K. H., Ohgaki H., Cavanee W. K. Glioblastoma. Kleihues P., Cavanee W. K. Pathology and Genetics of Tumours of the Nervous System. 1997;International Agency for Research on Cancer, Lyon.
29. Watanabe K., Tachibana O., Sato K., Yonekawa Y., Kleihues P., Ohgaki H. Incidence and timing of p53 mutations during astrocytoma progession in patients with multiple biopsies. Clin. Cancer Res. 3:1997;523-530.
30. Reyes-Mugica M., Rieger-Christ K., Ohgaki H., Ekstrand B. C., Helie M., Kleinman G., Yahanda A., Fearon E. R., Kleihues P., Reale M. A. Loss of DCC expression and glioma progression. Cancer Res. 57:1997;382-386.
31. von Deimling A., von Ammon K., Schoenfeld D., Wiestler O. D., Seizinger B. R., Louis D. N. Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol. 3:1993;19-26.
32. Lang F. F., Miller D. C., Koslow M., Newcomb E. W. Pathways leading to glioblastoma multiforme: A molecular analysis of genetic alterations in 65 astrocytic tumors. J. Neurosurg. 81:1994;427-436.
33. Biernat W., Kleihues P., Yonekawa Y., Ohgaki H. Amplification and overexpression of MDM2 in primary (de novo) glioblastomas. J. Neuropathol. Exp. Neurol. 56:1996;180-185.
34. Louis D. N. The p53 gene and protein in human brain tumors. J. Neuropathol. Exp. Neurol. 54:1994;65-73.
35. Hum. Gene Ther. 6:1995;1065-1124.
36. Oldfield E. H., Ram Z. Clinical protocol: Intrathecal gene therapy for the treatment of leptomeningeal carcinomatosis (phase I-II study). Hum. Gene Ther. 6:1995;55-85.
37. Izquierdo M., Martin V., Felipe P., Izquierdo J. M., Perez-Higueras A., Cortes M. L., Paz J. F., Isla A., Blazquez M. G. Human malignant brain tumor response to herpes simplex thymidine kinase (HSV-TK)/ganciclovir gene therapy. Gene Ther. 3:1996;491-495.
38. Ram Z., Culver K. W., Oshiro E. M., Viola J. J., De Vroom H. L., Otto E., Long Z., Chiang Y., McGarrity G. J., Muul L. M., Katz D., Blaese R. M., Oldfield E. H. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat. Med. 3:1997;1354-1361.
39. Klatzmann D., Valery C. A., Bensimon G., Marro B., Boyer O., Mokhtari K., Diquet B., Salzmann J. L., Philippon J. A phase I/II study of herpes simplex virus tipe 1 thymidine kinse "suicide" gene therapy for recurrent glioblastoma: Study group on gene therapy for glioblastoma. Hum. Gene Ther. 20:1998;2595-2604.
40. Moore A. E. Effects of viruses on tumors. Annu. Rev. Microbiol. 8:1954;393-410.
41. Smith R. R., Huebner R. J., Rowe W. P., Schatten W. E., Thomas L. B. Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer. 9:1956;1211-1218.
42. Deng Y., Yewdell J., Eisenlohr L., Bennink J. R. MHC affinity, peptide liberation, T cell repertoire, and immunodominance all contribute to the paucity of MHC class-I restricted peptides recognized by anti-viral CTL. J. Immunol. 158:1997;1507-15015.
43. Solnick D. Construction of an adenovirus-SV40 recombinant producing SV40 T antigen from an adenovirus late promoter. Cell. 24:1981;135-143.
44. Thummel C., Tjian R., Grodzicker T. Expression of SV40 T antigen under control of adenovirus promoters. Cell. 23:1981;825-836.
45. Guzman Y., Reichl H., Solnick D. Helper-free adenovirus type 5 vectors. Gluzman Y. Eukaryotic Viral Vectors. 1982;Cold Spring Harbor Laboratory, New York.
46. Parks R. J., Chen L., Anton M., Sankar U., Rudnicki M. A., Graham F. L. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc. Natl. Acad. Sci. USA. 93:1996;13565-13570.
47. Alemany R., Dai Y., Lou Y. C., Sethi E., Prokopenko E., Josephs S. F., Zhang W-W. Complementation of helper-dependent adenoviral vectors: Size effects and titer fluctuations. J. Virol. Methods. 68:1997;147-159.
48. Stow N. D. Cloning of a DNA fragment from the left-hand terminus of the adenovirus type 2 genome and its use in site-directed mutagenesis. J. Virol. 37:1981;171-180.
49. Berkner K. L., Sharp P. A. Generation of adenoviruses by transfection of plasmids. Nucleic Acids Res. 11:1983;6003-6020.
50. Graham F. L., Smiley J., Russell W. C., Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36:1977;59-72.
51. Ruben M., Bachetti S., Graham F. L. Covalently closed circles of adenovirus 5 DNA. Nature. 301:1983;172-174.
52. Ghosh-Choudhury G., Haj-Ahmad Y., Graham F. L. Protein IX, a minor component of the human adenovirus capsid, is essential for the packaging of full length genomes. EMBO J. 6:1987;1733-1739.
53. Mcgrory W. J., Bautista D. S., Graham F. L. A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5. Virology. 163:1988;614-617.
54. Crouzet J., Naudin L., Orsini C., Vigne E., Ferrero L., Le Roux A., Benoit P., Latta M., Torrent C., Branellec D., Denefle P., Mayaux J., Perricaudet M., Yeh P. Recombinatorial construction in Escherichia coli of infectious adenoviral genomes. Proc. Natl. Acad. Sci. USA. 94:1997;1414-1419.
55. White E. Regulation of apoptosis by adenovirus E1A and E1B oncogenes. Semin. Virol. 8:1998;505-513.
56. Yang Y., Li Q., Ertl C. J., Wilson J. M. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenovirus. J. Virol. 69:1995;2004-2015.
57. Fallaux F. J., Bout A., van der Belde I., van den Wollenberg D. J. M., Hehir K. M., Keegan J., Auger C., Cramer S. J., van Ormont H., van der Eb H., Valerio D., Hoeben R. C. New helper cells and matched early 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum. Gene Ther. 9:1998;1909-1917.
58. Andreanski S., Soroceanu L., Flotte E. R., Chou J., Markert J. M., Gillespie G. Y., Roizman B., Withley R. J. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res. 57:1997;1502-1509.
59. Bischof J. R., Kirn D. H., Williams A., Heise C., Horn S., Muna M., Ng L., Nye J. A., Sampson-Johanes A., Fattaey A., McCormick F. An adenovirus that replicates selectively in p53-deficient human tumor cells. Science. 274:1996;373-376.
60. Heise C., Sampson-Johanes A., Williams A., McCormick F., Von Hoff D. D., Kirn D. H. Onyx-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med. 3:1997;639-645.
61. Rothmann T., Hernstermann A., Whitaker N. J., Scheffner M., zur Hausen H. Replicacion of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J. Virol. 72:1998;9470-9478.
62. Goodrum F., Ornelles D. A. p53 status does not determine outcome of E1B 55-Kilodalton mutant adenovirus lytic infection. J. Virol. 72:1998;9479-9490.
63. Rodriguez R., Schuur E. R., Lim H. Y., Henderson G. A., Simons J. W., Henderson D. R. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 57:1997;2559-2563.
64. Shi Q., Wang Y., Worton R. Modulation of the specificity and activity of a cellular promoter in an adenoviral vector. Hum. Gene Ther. 8:1997;403-410.
65. Kirn D., Herminston T., McCormick F. ONYX-015: Clinical data are encoraging. Nat. Med. 4:1998;1341-1342.
66. Freytag S. O., Rogulski K. R., Paielii D. L., Gilbert J. F., Kim J. K. A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Hum. Gene Ther. 9:1998;1323-1333.
67. Yang Y., Trinchieri G., Wilson J. M. Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nat. Med. 1:1995;890-893.
68. Dmitriev I., Krasnykh V., Miller C. R., Wang M., Kashentseva E., Mikheeva G., Belousova N., Curiel D. T. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus-and adenovirus receptor-independent cell entry mechanism. J. Virol. 72:1998;9706-9713.
69. Yoshida Y., Sadata A., Zhang W., Saito K., Shinoura N., Hamada H. Generation of fiber-mutant recombinant adenoviruses for gene therapy of malignant glioma. Hum. Gene Ther. 9:1998;2503-2515.
70. Wolff G., Worgall S., van Rooijen N., Song W. R., Harvey B. G., Crystal R. G. Enhancement of in vivo adenovirus-mediated gene transfer and expression by prior depletion of tissue macrophages in the target organ. J. Virol. 71:1997;624-629.
71. Chillon M., Lee J. H., Fasbender A., Welsh M. J. Adenovirus complexed with polyethylene glycol and cationic lipid is shielded from neutralizing antibodies in vitro. Gene Ther. 5:1998;995-1002.